
|Articles|September 15, 2002
Ocular bacterial treatment in development
Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease
2
Lakhanpal on the first-visit conversation in geographic atrophy
3
Boosting premium IOL confidence through a mix-and-match approach
4
CVI Awareness Day: Why a normal eye exam can miss cerebral visual impairment
5








